Latest news

• Alzheon says data backs potential of Alzheimer's candidate

  The cognitive effect increased significantly with time, suggesting a potential disease-modifying effect of tramiprosate," they conclude. ... Tramiprosate is thought to work by inhibiting the aggregation of beta amyloid monomers into toxic oligomers.

• Signalling change

  Another once-promising anti-amyloid drug, tramiprosate, was also abandoned by Bellus Health due to inconclusive phase III study findings.

• Halted in its tracks

  Tramiprosate is a B-amyloid inhibitor that is currently in phase III development with Neurochem. ... Data presented at ICAD 2006 showed tramiprosate halts B-amyloid-induced neuronal cell death in rats.

• Dealing with dementia

  A promising late-stage candidate is Neurochem's Alzhemed (tramiprosate). This drug works by mimicking and binding to glycosaminoglycan (GAG), which promotes the formation of the amyloid-beta plaques.